Phaseline

Targets › PLASMODIUM

PLASMODIUM: drug programs, companies and trials

3 programs from 2 companies in 3 trials: 3 Phase 4; Infectious disease; next expected readout Dec 2027.

Open in Phaseline: the race on PLASMODIUM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Yale UniversityArtemether-lumefantrine (AL)
Artemisinin derivative and aminoquinoline antimalarial combination
PLASMODIUMPhase 4MalariaDec 2027
Yale UniversityArtesunate-amodiaquine (AS-AQ)
Artemisinin derivative and aminoquinoline antimalarial combination
PLASMODIUMPhase 4MalariaDec 2027
University of OxfordDHA/piperaquine and SLD-PQ
Artemisinin derivative and quinoline antimalarial
PLASMODIUMPhase 4Plasmodium Falciparum MalariaFeb 2028

Conditions

Malaria (2) Plasmodium Falciparum Malaria (1)

Modalities

small molecule (2), mixed (1)

Companies

Yale University (2) University of Oxford (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.